The MNOV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNOV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MNOV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View MNOV Detailed Price Forecast - CNN Money | View MNOV Detailed Summary - Google Finance | ||
View MNOV Detailed Summary - Yahoo! Finance | View MNOV Stock Research & Analysis - Zacks.com |
View MNOV Trends & Analysis - Trade-Ideas | View MNOV Major Holders - Barrons | ||
View MNOV Call Transcripts - NASDAQ | View MNOV Breaking News & Analysis - Seeking Alpha | ||
View MNOV Annual Report - CompanySpotlight.com | View MNOV OTC Short Report - OTCShortReport.com | ||
View MNOV Fundamentals - TradeKing | View MNOV SEC Filings - Bar Chart | ||
View Historical Prices for MNOV - The WSJ | View Performance/Total Return for MNOV - Morningstar | ||
View the Analyst Estimates for MNOV - MarketWatch | View the Earnings History for MNOV - CNBC | ||
View the MNOV Earnings - StockMarketWatch | View MNOV Buy or Sell Recommendations - MacroAxis | ||
View the MNOV Bullish Patterns - American Bulls | View MNOV Short Pain Metrics - ShortPainBot.com |
View MNOV Stock Mentions - StockTwits | View MNOV Stock Mentions - PennyStockTweets | ||
View MNOV Stock Mentions - Twitter | View MNOV Investment Forum News - Investor Hub | ||
View MNOV Stock Mentions - Yahoo! Message Board | View MNOV Stock Mentions - Seeking Alpha |
View Insider Transactions for MNOV - SECform4.com | View Insider Transactions for MNOV - Insider Cow | ||
View MNOV Major Holdings Summary - CNBC | View Insider Disclosure for MNOV - OTC Markets | ||
View Insider Transactions for MNOV - Yahoo! Finance | View Institutional Holdings for MNOV - NASDAQ |
View MNOV Stock Insight & Charts - FinViz.com | View MNOV Investment Charts - StockCharts.com | ||
View MNOV Stock Overview & Charts - BarChart | View MNOV User Generated Charts - Trading View |
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Posted on Tuesday April 02, 2024
LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago. The
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
Posted on Tuesday March 26, 2024
LA JOLLA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. Once issued, this patent is expected to expire
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
Posted on Wednesday March 20, 2024
LA JOLLA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled “STUDY PROTOCOL TO EVALUATE MN-001’S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM)” and “MN-002, THE METABOLITE
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
Posted on Wednesday March 20, 2024
Just because a business does not make any money, does not mean that the stock will go down. For example, although...